Randomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease
2026年6月8日 更新者:Damodar Sharma、Pokhara Academy of Health Sciences, Western Regional Hospital
Comparative Effectiveness of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease: A Randomized Clinical Trial
Dry Eye Disease (DED) is a common, chronic ocular surface disorder characterized by tear film instability, ocular discomfort, and visual disturbance.
Artificial tears are the first-line treatment for DED; however, many formulations contain preservatives such as benzalkonium chloride (BAK) and stabilized oxychloro complex (SOC) which may cause ocular surface toxicity with long-term use.
Preservative-free artificial tears are considered safer alternatives, but comparative clinical evidence from Nepal is limited.
This study aims to compare the clinical efficacy and safety of preservative-free versus preserved carboxymethylcellulose (CMC) artificial tears in patients with Dry Eye Disease.
This will be a hospital-based, randomized, double-blinded controlled clinical trial conducted in the ophthalmology outpatient department of a tertiary care hospital in Nepal.
A total of 80 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive either preservative-free CMC artificial tears or preserved CMC artificial tears for a duration of eight weeks.
Participant, investigators, outcome assessors and data analysts will remain blinded to minimize assessment bias.
Baseline assessments will include the Ocular Surface Disease Index (OSDI) questionnaire, Tear Film Break-Up Time (TBUT), Schirmer's test (without anesthesia), and corneal fluorescein staining.
These outcomes will be reassessed at four and eight weeks.
Safety and tolerability will be evaluated by documenting patient-reported adverse effects.
Data will be analyzed using appropriate statistical methods, with a p-value of less than 0.05 considered statistically significant.
The study is expected to demonstrate superior safety and improved ocular surface outcomes with preservative-free artificial tears compared to preserved formulations.
Findings from this research will provide local evidence to guide rational prescribing practices and improve the management of Dry Eye Disease in Nepal.
研究概览
地位
尚未招聘
条件
研究类型
介入性
注册 (估计的)
80
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Damodar Sharma, MBBS, MD
- 电话号码:+977-9856022583
- 邮箱:damodars@outlook.com
研究联系人备份
- 姓名:Jamuna Gurung, MBBS, MD
- 电话号码:+977-9860314317
- 邮箱:jamunaorama@gmail.com
学习地点
-
-
Gandaki
-
Pokhara、Gandaki、尼泊尔、33700
- Pokhara Academy of Health Sciences
-
接触:
- Phanindra Prasad Poudel, Msc, PhD
- 电话号码:+977-9846115569
- 邮箱:poudelpha@gmail.com
-
首席研究员:
- Damodar Sharma, MBBS, MD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age ≥18 years
- Clinical diagnosis of Dry Eye Disease (OSDI >13 and TBUT <10 seconds)
- Willingness to provide written informed consent
Exclusion Criteria:
- Contact lens use
- Active ocular infection or inflammation
- History of ocular surgery within the past 6 months
- Use of systemic immunosuppressive therapy
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Patients with DED receiving CMC with preservative
40 patients will receive drops in the eye
|
A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preserved CMC artificial tears for a duration of eight weeks.
其他名称:
|
|
有源比较器:Patients with DED receiving CMC without preservative
40 patients will receive drops in the eye
|
A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preservative-free CMC artificial tears for a duration of eight weeks.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Ocular Surface Disease Index (OSDI) Score
大体时间:From enrollment to the end of treatment at 8 weeks
|
Ocular Surface Disease Index (OSDI) Score.
The OSDI is a 12-item questionnaire that assesses dry eye symptoms and their impact on vision-related functioning.
Total scores range from a minimum of 0 to a maximum of 100.
Higher scores indicate more severe dry eye symptoms and a worse outcome.
|
From enrollment to the end of treatment at 8 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tear Film Break-Up Time (TBUT)
大体时间:From enrollment to the end of treatment at 8 weeks
|
Tear Film Break-Up Time (TBUT).
This measures the time elapsed in seconds between a complete blink and the appearance of the first dry spot on the cornea.
It does not have a strict maximum value, but a minimum of 0 seconds.
Higher values indicate a more stable tear film and a better outcome.
|
From enrollment to the end of treatment at 8 weeks
|
|
Schirmer's Test (without anesthesia)
大体时间:From enrollment to the end of treatment at 8 weeks
|
This measures basic tear production by placing a paper strip inside the lower eyelid for 5 minutes.
It is measured in millimeters (mm) of wetting, with a minimum of 0 mm and a typical maximum of 35 mm.
Higher values indicate better tear production and a better outcome.
|
From enrollment to the end of treatment at 8 weeks
|
|
Corneal Fluorescein Staining Score
大体时间:From enrollment to the end of treatment at 8 weeks
|
Corneal Fluorescein Staining Score using the Oxford Grading Scheme.
This scale assesses the severity of damage to the surface of the eye.
The total score ranges from a minimum of 0 to a maximum of 15.
Higher scores indicate greater damage to the cornea and a worse outcome.
|
From enrollment to the end of treatment at 8 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability (Adverse Effects)
大体时间:From enrollment to the end of treatment at 8 weeks
|
Patient-reported adverse effects will be systematically documented throughout the trial to evaluate the safety and tolerability of the respective artificial tear formulations
|
From enrollment to the end of treatment at 8 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2027年1月1日
研究完成 (估计的)
2027年3月1日
研究注册日期
首次提交
2026年6月3日
首先提交符合 QC 标准的
2026年6月3日
首次发布 (实际的)
2026年6月9日
研究记录更新
最后更新发布 (实际的)
2026年6月10日
上次提交的符合 QC 标准的更新
2026年6月8日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.